Upgrade to SI Premium - Free Trial

Vertex Pharma (VRTX) Tops Q3 EPS by 22c, Beats on Revenues; Boosts FY17 Revenue Outlook

October 25, 2017 4:07 PM

Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $0.53, $0.22 better than the analyst estimate of $0.31. Revenue for the quarter came in at $550 million versus the consensus estimate of $520.13 million.

2017 Financial Guidance:

Vertex today increased its total 2017 CF product revenue guidance, including ORKAMBI and KALYDECO revenue guidance, and reiterated its combined GAAP and non-GAAP R&D and SG&A expense guidance:

GUIDANCE:

Vertex Pharma sees FY2017 revenue of $2.1-2.5 billion, versus the consensus of $2.3 billion.

Revenues:

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

Categories

Earnings Guidance Hot Guidance